Drugs in Dev. Ophthalmology
Phase I
Switzerland 
Lead Product(s) : BI 771716
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDR-Life Achieves Fourth Milestone with Boehringer in Phase 1 Geographic Atrophy Trial
Details : BI 771716 is an antibody fragment-based compound, which is being evaluated in the early-stage clinical trial studies for the treatment of patients with geographic atrophy.
Product Name : BI 771716
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
April 30, 2024
Lead Product(s) : BI 771716
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 771716
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 771716, developed with technology licensed from CDR-Life, is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology.
Product Name : BI 771716
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 12, 2023
Lead Product(s) : BI 771716
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Great Health Companion Group
Deal Size : Undisclosed
Deal Type : Partnership
Kinarus Therapeutics Engages Great Health Companion Group to Explore Partnerships in China
Details : KIN001 is a patented combination of two active pharmaceutical ingredients (APIs): pamapimod and pioglitazone. Pamapimod is a highly selective clinical stage small molecule inhibitor of the p38 MAP kinase signaling pathway.
Product Name : KIN001
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 16, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Great Health Companion Group
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIN001 (pamapimod) has been shown to reduce pathological blood vessel growth (neovascularization) in the choroid of the eye in preclinical models of wAMD.
Product Name : KIN001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2022
Lead Product(s) : Pamapimod,Pioglitazone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 4D-110
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Details : Roche requested that 4DMT conclude the Roche-funded 4D-110 trial in advanced choroideremia patients as a result of Roche’s assessment of a change in the risk-benefit profile.
Product Name : 4D-110
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 24, 2021
Lead Product(s) : 4D-110
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : 4D Molecular Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Reset All
